WO2004066908A3 - Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee - Google Patents

Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee Download PDF

Info

Publication number
WO2004066908A3
WO2004066908A3 PCT/FR2004/000088 FR2004000088W WO2004066908A3 WO 2004066908 A3 WO2004066908 A3 WO 2004066908A3 FR 2004000088 W FR2004000088 W FR 2004000088W WO 2004066908 A3 WO2004066908 A3 WO 2004066908A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
polypeptide
composition containing
active substances
cationic lipids
Prior art date
Application number
PCT/FR2004/000088
Other languages
English (en)
Other versions
WO2004066908A2 (fr
Inventor
Jean Haensler
Original Assignee
Aventis Pasteur
Jean Haensler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Jean Haensler filed Critical Aventis Pasteur
Publication of WO2004066908A2 publication Critical patent/WO2004066908A2/fr
Publication of WO2004066908A3 publication Critical patent/WO2004066908A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention a pour objet une composition qui comprend un polynucléotide ou un polypeptide chargé négativement et le bromure de 2-propanaminium, N-[2­(acetyloxy)ethyl]-1,3-bis(hexadecyloxy)-N,N-dimethyl-1,3-dioxo- ou un composé de structure et d'action équivalente. Un tel composé permet de délivrer de manière sélective le 20 polynucléotide ou le polypeptide dans des tissus riches en récepteur acétylcholine. Ainsi, la composition selon l'invention est utile en transfection in vitro ou ex vivo, et dans le domaine de la thérapie génique, de la vaccination et de l'immunothérapie.
PCT/FR2004/000088 2003-01-17 2004-01-16 Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee WO2004066908A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300489 2003-01-17
FR03/00489 2003-01-17

Publications (2)

Publication Number Publication Date
WO2004066908A2 WO2004066908A2 (fr) 2004-08-12
WO2004066908A3 true WO2004066908A3 (fr) 2004-10-07

Family

ID=32799432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000088 WO2004066908A2 (fr) 2003-01-17 2004-01-16 Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee

Country Status (1)

Country Link
WO (1) WO2004066908A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037194A1 (fr) * 1995-05-26 1996-11-28 Somatix Therapy Corporation Vehicules d'apport medicamenteux comprenant des complexes d'acides nucleiques/de lipides stables
WO1999025320A1 (fr) * 1997-11-19 1999-05-27 Georgetown University Apport cible de gene dans un liposome vecteur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037194A1 (fr) * 1995-05-26 1996-11-28 Somatix Therapy Corporation Vehicules d'apport medicamenteux comprenant des complexes d'acides nucleiques/de lipides stables
WO1999025320A1 (fr) * 1997-11-19 1999-05-27 Georgetown University Apport cible de gene dans un liposome vecteur

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BENNETT ET AL: "CATIONIC LIPID-MEDIATED GENE DELIVERY TO MURINE LUNG: CORRELATION OF LIPID HYDRATION WITH IN VIVO TRANSFECTION ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, 5 December 1997 (1997-12-05), pages 4069 - 4078, XP002088280, ISSN: 0022-2623 *
FORSSEN ERIC ET AL: "Ligand-targeted liposomes", ADVANCED DRUG DELIVERY REVIEWS, vol. 29, no. 3, 2 February 1998 (1998-02-02), pages 249 - 271, XP002290051, ISSN: 0169-409X *
GAUCHERON JEROME ET AL: "Synthesis and properties of novel tetraalkyl cationic lipids", BIOCONJUGATE CHEMISTRY, vol. 13, no. 3, May 2002 (2002-05-01), pages 671 - 675, XP002290052, ISSN: 1043-1802 *
MENGER F M ET AL: "SPECIFIC ENZYME-INDUCED DECAPSULATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 113, 1991, pages 5467 - 5468, XP000942189, ISSN: 0002-7863 *
SONG L Y ET AL: "Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1558, no. 1, 2 January 2002 (2002-01-02), pages 1 - 13, XP004326959, ISSN: 0005-2736 *
XIAOHUAI ZHOU ET AL: "TARGETED DELIVERY OF DNA BY LIPOSOMES AND POLYMERS", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 19, no. 1 / 3, 1 March 1992 (1992-03-01), pages 269 - 274, XP000261538, ISSN: 0168-3659 *
ZHOU X ET AL: "DNA TRANSFECTION MEDIATED BY CATIONIC LIPOSOMES CONTAINING LIPOPOLYLYSINE: CHARACTERIZATION AND MECHANISM OF ACTION", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1189, 1994, pages 195 - 203, XP000619500, ISSN: 0005-2736 *

Also Published As

Publication number Publication date
WO2004066908A2 (fr) 2004-08-12

Similar Documents

Publication Publication Date Title
US20210047640A1 (en) Compositions and methods for treating hypertriglyceridemia
AU2013222179B2 (en) Trialkyl cationic lipids and methods of use thereof
WO2006079019A3 (fr) Preparations peptidiques therapeutiques a stabilite accrue
EP1927660A3 (fr) Procédé pour fournir l'ADN à des cellules musculaires utilisant des virions de virus adéno associés recombinants
EP2353651A3 (fr) Utilisation de composés inhibant l'apoptose dans le traitement des troubles neurologiques dégénératifs
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
EP2325193A3 (fr) Procédés et compositions permettant l'utilisation thérapeutique de l'interférence ARN
EP2578685A3 (fr) ARN contenant des nucléosides modifiées et leurs procédés d'utilisation
EP2253706A3 (fr) Modulation anti-sens de l'expression de la kinésine de type 1
AU2003258686A1 (en) Vesicle-encapsulated corticosteroids for the treatment of cancer
CA2945930A1 (fr) Compositions comprenant des derives d'osteopontine pour inhiber la croissance capillaire
TW201919653A (zh) 用於治療ｂ型肝炎之治療組合物及方法
WO2004019893A3 (fr) Modulateurs d'angiogenese
WO2005086773A3 (fr) Methode d'administration de proteines therapeutiques dans le compartiment intradermique
WO2004066908A3 (fr) Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee
WO2005115461A3 (fr) Composition pharmaceutique modulant l'activite d'un triglyceride hydrolase
WO2005069855A3 (fr) Modulateurs d'angiogenese
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
WO2004098451A3 (fr) Dispositifs medicaux enrobes et procedes de fabrication associes
WO2002078610A3 (fr) Pak2: modulateurs de l'activation lymphocytaire
AU2022328856A1 (en) Lipid nanoparticle formulations
WO2001024764A3 (fr) Compositions de ciblage de cellules et procedes d'utilisation de celles-ci
EP1385948A4 (fr) Acides nucleiques pour inhiber l'expression de proteines hairless et leurs methodes d'utilisation
PL1618195T3 (pl) Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase